These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2721542)

  • 1. Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.
    Horiuchi T; Johno I; Hasegawa T; Kitazawa S; Goto M; Hata T
    Eur J Clin Pharmacol; 1989; 36(2):175-80. PubMed ID: 2721542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma free fatty acids and protein binding of disopyramide during haemodialysis.
    Horiuchi T; Johno I; Kitazawa S; Goto M; Hata T
    Eur J Clin Pharmacol; 1987; 33(3):327-9. PubMed ID: 3691623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma protein binding of disopyramide by equilibrium dialysis and ultrafiltration.
    David BM; Tjokrosetio R; Ilett KF
    Ther Drug Monit; 1983; 5(1):81-6. PubMed ID: 6845403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.
    Haughey DB; Kraft CJ; Matzke GR; Keane WF; Halstenson CE
    Am J Nephrol; 1985; 5(1):35-9. PubMed ID: 3881959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of unbound fraction of disopyramide in plasma: a comparison of equilibrium dialysis, ultrafiltration through dialysis membranes and ultrafree anticonvulsant drug filters.
    Norris RL; Ahokas JT; Ravenscroft PJ
    J Pharmacol Methods; 1982 Jan; 7(1):7-14. PubMed ID: 7070107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting the binding of disopyramide to serum proteins.
    Shaw LM; Altman R; Thompson BC; Fields L
    Clin Chem; 1985 Apr; 31(4):616-9. PubMed ID: 3884182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of free disopyramide plasma concentrations using ultrafiltration and enzyme multiplied immunoassay.
    Raghow G; Meyer MC; Straughn AB
    Ther Drug Monit; 1985; 7(4):466-71. PubMed ID: 3909539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
    David BM; Ilett KF; Whitford EG; Stenhouse NS
    Br J Clin Pharmacol; 1983 Apr; 15(4):435-41. PubMed ID: 6849779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of disopyramide to alpha 1-acid glycoprotein in plasma measured by competitive equilibrium dialysis.
    Norris RL; Ahokas JT; Ravenscroft PJ; Henry M
    J Pharm Sci; 1984 Jun; 73(6):824-6. PubMed ID: 6737271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Displacement of lidocaine from human plasma proteins by disopyramide.
    Bonde J; Jensen NM; Burgaard P; Angelo HR; Graudal N; Kampmann JP; Pedersen LE
    Pharmacol Toxicol; 1987 Feb; 60(2):151-5. PubMed ID: 3575249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective binding of disopyramide to plasma proteins.
    Valdivieso L; Giacomini KM; Nelson WL; Pershe R; Blaschke TF
    Pharm Res; 1988 May; 5(5):316-8. PubMed ID: 3244643
    [No Abstract]   [Full Text] [Related]  

  • 13. The acute changes in serum binding of disopyramide and flecainide after myocardial infarction.
    Caplin JL; Johnston A; Hamer J; Camm AJ
    Eur J Clin Pharmacol; 1985; 28(3):253-5. PubMed ID: 4007029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of blood collection technique on serum and plasma protein binding of disopyramide.
    Haughey DB; Lima JJ
    Eur J Clin Pharmacol; 1982; 22(2):185-9. PubMed ID: 7094989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
    Shaw LM; Doherty JU; Waxman HL; Josephson ME
    Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.
    Echizen H; Saima S; Ishizaki T
    Br J Clin Pharmacol; 1987 Aug; 24(2):199-206. PubMed ID: 3620294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers.
    Echizen H; Nakura M; Saotome T; Minoura S; Ishizaki T
    Br J Clin Pharmacol; 1990 Apr; 29(4):423-30. PubMed ID: 2183867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein.
    Haughey DB; Steinberg I; Lee MH
    J Pharm Pharmacol; 1985 Apr; 37(4):285-8. PubMed ID: 2860235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the binding capacity of alpha-1-acid glycoprotein in patients with renal insufficiency.
    Kishino S; Nomura A; Di ZS; Sugawara M; Iseki K; Kakinoki S; Kitabatake A; Miyazaki K
    Ther Drug Monit; 1995 Oct; 17(5):449-53. PubMed ID: 8585106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of disopyramide enantiomers for sites on plasma protein.
    Lima JJ
    Life Sci; 1987 Dec; 41(26):2807-13. PubMed ID: 3695808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.